Glucagon-like peptide receptor agonists (GLP-1 RA) are the current financial rainmakers for BIG PHARMA.
Shi et al from Harvard reported recently in JAMA Cardiology.
Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion. Quantifying the number of US adults eligible for semaglutide may guide future policies for this high-cost therapy and clarify potential implications for pharmaceutical spending.
The authors conclude that approximately 137 million adults or half the of the US population could have a clinical indication for once weekly GLP-1 RA drugs. This budget breaking conclusion no doubt will have to be addressed by the incoming HHS administration led by Robert F. Kennedy, Jr.
Hellbound and Down 